The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An analysis of STAT3 polymorphism on outcomes of interferon-alpha treatment in patients with metastatic renal cell carcinoma.
M. Eto
No relevant relationships to disclose
T. Kamba
No relevant relationships to disclose
H. Miyake
No relevant relationships to disclose
M. Fujisawa
No relevant relationships to disclose
K. Yoshida
No relevant relationships to disclose
H. Uemura
No relevant relationships to disclose
T. Tsukamoto
No relevant relationships to disclose
Y. Katsuoka
No relevant relationships to disclose
A. Matsubara
No relevant relationships to disclose
K. Nishimura
No relevant relationships to disclose
T. Nakamura
No relevant relationships to disclose
O. Ogawa
No relevant relationships to disclose
S. Naito
No relevant relationships to disclose